All In Biotech

Drug Trial Radar · NCT01036139

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase

Last checked: Nov 19, 2026Latest source record: Apr 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

268

Actual

Start

Dec 2009

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
BioprojetAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 21, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649 in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's Disease.

Conditions

  • Parkinson's Disease

Interventions

  • BF2.649 (pitolisant)Drug

    1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ESS change (Epworth Sleepiness Scale)Time frame: at week 12 / 52 versus baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pr Arnulf

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.